Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the ...

Oveporexton is designed to promote wakefulness and reduce abnormal REM-sleep-like phenomena, including cataplexy, in patients with NT1.

Easier access to naturalised citizenship is one of several proposals outlined in the framework to boost Defence Forces numbers and increase diversity within the organisation. The Government has ...

Chris Andrews claims he was defamed in Irish Times article concerning Sinn Féin response to October 7th Hamas attack on ...

ASX gallium stocks have entered the radar amidst global supply concerns driven by the metal's use in advanced radar ...

Noida: The Noida administration has invited applications to set up its first civil defence unit, calling on residents to ...

Volatus Aerospace Inc. (TSXV: FLT; OTCQB: TAKOF; Frankfurt: A3DP5Y/ABB.F) (“Volatus” or the “Company”), a next-generation aerospace and defence company delivering dual-use uncrewed systems, aerial ...

Engagement Strengthens European Investor Outreach as Critical Minerals and Defence Partnerships AccelerateOttawa, Ontario--(Newsfile Corp. - ...

The FDA has started a priority review of Takeda's oveporexton for sleep disorder narcolepsy, setting up a decision in the third quarter of the year. The acceptance of the new drug application (NDA) ...

Built around Intel’s 11th Gen Tiger Lake processor, the new rugged onboard computer targets 24×7 mission-critical deployments ...

Brenton Tarrant’s case before the Court of Appeal this week raises simple questions that help explain how New Zealand’s legal ...

The High Court in Accra has dismissed an application seeking to refer portions of a practice direction, which require accused persons in criminal trials to file the list of defence witnesses and their ...